VRL/SEC/NSE/92

March 11th, 2013

National Stock Exchange of India Ltd..
5th Floor , Exchange Plaza
Bandra (E), Mumbai- 400 051

Sub. : Venus Remedies' MEROPENEM receives market authorization in Mexico

Dear Sir/Madam,

This is to inform you that Venus Remedies Limited has has received grant of market authorisation from COFEPRIS the Drug Regulatory Authority of Mexico, for its Meropenem 500mg and Meropenem 1000mg in Mexico.

This grant from COFEPRIS (*La Comisión Federal para la Protección contra Riesgos Sanitarios*) the Latin America's most stringent regulatory authority, is further endorsement to Venus Remedies' R&D capabilities and its expertise in developing world class products. Market authorization for Meropenem will enable Venus Remedies to launch its first product in Mexico and will strengthen its position in Latin America where Venus is currently exporting to various countries of LAC such as Columbia, Peru, Guatemala, Dominican Republic, Jamaica, Bahamas and the Caribbean.

Receiving a market authorization grant at this point of time when the innovator's product has already gone off patent is going to be an advantage for the company. At present, Meropenem sales account for US$ 16.3 million in Mexico, of which, major share of 80% is with innovator's product "MERREM" and rest with other local companies. Venus Remedies with its dedicated penems EU GMP certified manufacturing facility in Baddi, India, is all set to expand its footprints across the globe. It already has 73 Marketing Authorizations for Meropenem across the world while product registrations from 13 countries are under process and are expected within this year only.

The company is planning to launch the product in Mexico within the first quarter of fiscal year 2013-2014.

Meropenem a broad spectrum anti-bacterial agent of carbapenem family, indicated an empirical therapy prior to the identification of causative organisms, or for disease caused by single or multiple susceptible bacteria in both adults and children with multiple serious infections.

Presently, Venus is already selling Meropenem in various markets and is in the process of further extending its sales operations in the most regulated markets which includes countries like Netherlands, France, Italy, Germany and few more.

Yours faithfully,
for VENUS REMEDIES LIMITED.

Ramanjit

Ramanjit Kaur
Deputy Manager
Corporate Communication

VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase- I,
Panchkula (Hry.) 134113, India
Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manimajra, Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.venusmedicineresearchcentre.com

MOODY INTERNATIONAL
UKAS QUALITY MANAGEMENT
UKAS ENVIRONMENTAL MANAGEMENT

Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566
Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272
Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-89269 W...

FROM :VENUS FAX NO. :0172 2565566 11 Mar. 2013 11:37 P 1